Journal of Immunology Research

Journal of Immunology Research / 2016 / Article
Special Issue

Clinical and Experimental Immunomodulation 2016

View this Special Issue

Review Article | Open Access

Volume 2016 |Article ID 1459394 | 16 pages |

Adjuvants: Classification, Modus Operandi, and Licensing

Academic Editor: Lenin Pavon
Received18 Feb 2016
Revised02 Apr 2016
Accepted11 Apr 2016
Published04 May 2016


Vaccination is one of the most efficient strategies for the prevention of infectious diseases. Although safer, subunit vaccines are poorly immunogenic and for this reason the use of adjuvants is strongly recommended. Since their discovery in the beginning of the 20th century, adjuvants have been used to improve immune responses that ultimately lead to protection against disease. The choice of the adjuvant is of utmost importance as it can stimulate protective immunity. Their mechanisms of action have now been revealed. Our increasing understanding of the immune system, and of correlates of protection, is helping in the development of new vaccine formulations for global infections. Nevertheless, few adjuvants are licensed for human vaccines and several formulations are now being evaluated in clinical trials. In this review, we briefly describe the most well known adjuvants used in experimental and clinical settings based on their main mechanisms of action and also highlight the requirements for licensing new vaccine formulations.

1. Introduction

Vaccination is one of the most efficient strategies for infectious diseases prevention. According to the World Health Organization (WHO), vaccination saves 5 lives every minute and will save over 25 million lives from 2011 to 2020. Traditional vaccine approaches like inactivated or live-attenuated viruses, although highly effective and immunogenic, present safety concerns. Despite being safer, subunit vaccines are normally less immunogenic/effective and need to be delivered together with an adjuvant. Hence, adjuvants are essential for enhancing and directing the adaptative immune response to vaccine antigens.

The term adjuvant comes from the Latin adjuvare, which means to help or aid [1]. Adjuvants can be defined as substances that increase immunogenicity of a vaccine formulation when added/mixed to it. The choice of the adjuvant is of utmost importance as it can stimulate strong humoral and cell mediated immunity indispensable for protection against some pathogens. In addition, the balance between the adjuvant properties and adverse effects plays a critical role in the selection.

The history of adjuvant discovery begins with Gaston Ramon, a veterinary working at the Pasteur Institute in 1920, that described the term adjuvant after he observed that higher specific antibody titers were detected in horses that developed abscesses at the injection site [2]. To confirm the hypothesis, he induced sterile abscesses at the injection site with starch or breadcrumbs together with inactivated toxin and confirmed that substances capable of inducing inflammation at the injection site also improved the production of antisera [3]. About the same time, Glenny et al. discovered the adjuvant effect of aluminum salts [4], and since then billions of alum-based vaccine doses have been administered to people. Jules Freund developed, in 1930, a powerful adjuvant composed of a water-in-mineral oil emulsion that also contained heat-killed mycobacteria (Mycobacterium tuberculosis or others) [5]. Although highly effective, complete Freund’s adjuvant (CFA) is also reactogenic and frequently induces granulomas, sterile abscesses, and ulcerative necrosis at the site of inoculation, which precludes it from being used in human vaccines. Figure 1 shows a timeline of adjuvant discovery.

A variety of compounds with adjuvant properties currently exist, and they seem to exert their functions through different mechanisms of action. Mineral salts, emulsions, microparticles, saponins, cytokines, microbial components/products, and liposomes have all been evaluated as adjuvants [68]. Nevertheless, few adjuvants are licensed for human use and several formulations are now being evaluated in clinical trials. In many cases, their use is empirical. Over the past years, many efforts have been made to investigate how and why adjuvants work. Recent advances have shown that adjuvants can (i) increase the biological half-life of vaccines, (ii) increase antigen uptake by antigen presenting cells (APCs), (iii) activate/mature APCs (e.g., dendritic cells), (iv) induce the production of immunoregulatory cytokines, (v) activate inflammasomes, and (vi) induce local inflammation and cellular recruitment [3, 9].

Independently of their mechanism of action, adjuvants have been traditionally used in the formulation of vaccines in an attempt to (i) decrease the amount of antigen, (ii) reduce the number of doses required to induce protective immunity, (iii) induce protective responses more rapidly, and (iv) increase the rate of seroconversion in special populations (the elderly, immunocompromised individuals, individuals with chronic disease, neonates and infants) [9].

2. Classification of Adjuvants

Different criteria may be used to group adjuvants in order to allow a rational comparison. Adjuvants can be classified according to their physicochemical properties, origin, and mechanisms of action [10]. Based on their mechanisms of action, adjuvants can be divided into delivery systems (particulate) and immune potentiators (immunostimulatory) [11]. Mucosal adjuvants are a class of compounds that can fit in both of the previously described categories (Table 1).


Delivery systems
 Mineral saltsAluminum salts [alum]
Calcium phosphate
 Lipid particlesIncomplete Freund’s adjuvant
 MicroparticlesVirus-like particles
PLA (polylactic acid), PLG (poly[lactide-coglycolide])

Immune potentiatorsdsRNA: Poly(I:C), Poly-IC:LC
Monophosphoryl lipid A (MPL), LPS
Imidazoquinolines: imiquimod (R837), resiquimod (848)
CpG oligodeoxynucleotides (ODN)
Muramyl dipeptide (MDP)
Saponins (QS-21)

Mucosal adjuvantsCholera toxin (CT)
Heat-labile enterotoxin (LTK3 and LTR72)

Delivery systems can function as carriers to which antigens can be associated. Also, they create local proinflammatory responses that recruit innate immune cells to the site of injection [12]. Hence, it has been proposed that this type of adjuvants can activate innate immunity.

In a simplistic definition, the role of immune potentiators is to activate innate immune responses through pattern-recognition receptors (PRRs) or directly (e.g., cytokines). Pattern-recognition receptors (PRRs) consist of different classes of receptors [Toll-like receptors (TLRs), nucleotide-binding oligomerization domain- (NOD-) like receptors (NLRs), and the retinoic acid-inducible gene-I- (RIG-I-) like receptors (RLRs)] that are widely expressed on immune cells. Their engagement by pathogen-associated molecular patterns (PAMPs) triggers the activation of such innate cells that can ultimately mature/migrate to other tissues and produce cytokines and chemokines [13].

2.1. Delivery Systems
2.1.1. Mineral Salts

Delivery systems (particulate adjuvants) cover a wide range of materials such as aluminum salts (alum), lipid particles, and microparticles. Alum is by far the most widely used adjuvant since its introduction in the 1920s [14]. This adjuvant is in the formulation of licensed vaccines against Hepatitis A (HAV), Hepatitis B (HBV), diphtheria/tetanus/pertussis (DTP), human papillomavirus (HPV), Haemophilus influenza type B (HiB), and Pneumococcus.

Until recently, alum was believed to owe its adjuvant properties to the slow release of the antigen associated with it [15]. However, several reports demonstrated that if “antigen-alum depot” was removed after immunization, the immune response remained unaltered [16, 17], demonstrating that the depot effect and slow release of the antigen were not responsible for its adjuvant activity. Indeed, recent evidence showed that alum can activate the innate immune response [18, 19]. Aluminum-containing adjuvants are a class of adjuvants that do not use the classical TLRs and MyD88 or TRIF signaling pathways to activate innate immunity. Instead, they are sensed by NOD-like receptors (NLRs) through direct activation of NLRP3/NALP3 inflammasome complex or by the release of uric acid [18, 20, 21]. Another feature of alum is its ability to reduce antigen degradation [22].

However, for some vaccine formulations, alum does not elicit protective and sustained immune responses. This is because aluminum-containing adjuvants preferentially induce Th2 responses (characterized by antibody production), and for some pathogens a Th1 immune response (including cytotoxic CD8 T cells) is required [14, 23]. Hence, for such vaccines alum should not be used, at least not alone.

2.1.2. Emulsion Adjuvants

Freund’s Adjuvants. Complete Freund’s adjuvant (CFA) is a water-in-oil emulsion that contains heat-killed mycobacteria and is a classic “gold standard” representative of this group of adjuvants. In general, CFA is used to evaluate the immunogenicity of antigens in mice and on the induction of autoimmune diseases like uveitis and experimental autoimmune encephalomyelitis. In order to induce autoimmunity, evidence suggests that the components of mycobacteria direct T-lymphocytes to acquire a Th1 pattern that mediates delayed type hypersensitivity (DTH). One of the major concerns regarding the use of CFA is the induction of strong long-lasting local inflammation that may be painful to the animal often leading to ulcer at the site of injection [24]. Hence, there are numerous regulatory guidelines to work with CFA in experimental animals [25, 26].

Incomplete Freund’s adjuvant (IFA) is also a water-in-oil emulsion, but without mycobacteria. In the 50s, the use of IFA as an adjuvant in a human influenza vaccine led to higher long-lived antibody titers when compared to the same formulation without the adjuvant [27]. Its adjuvant activity is the result of a continuous release of the antigen from the oily deposit, an increased antigen lifetime, and the stimulation of local innate immunity, as it enhances phagocytosis, leukocyte infiltration, and cytokine production [28]. Although there is a consensus that the use of IFA in humans is hampered by the strong side effects, a survey conducted by the WHO reported that immunization of one million individuals with IFA showed severe side effects, such as sterile abscesses, in 40,000 [29]. Hence, due to the balance between potency and side effects, there are several completed clinical trials using IFA in vaccine candidates for HIV infection (see, access number: NCT00381875), melanoma (NCT00003224,  NCT00706992, and NCT00085189), renal carcinoma (NCT00001703), and also multiple sclerosis (NCT02200718).

MF59. MF59 is a water-in-oil squalene based emulsion that is currently licensed as part of a flu vaccine (Fluad, Seqirus) for individuals >65 years old. Initially, the vaccine focused on elderly subjects but was later tested in the second major flu risk group, young children and infants, and was successful in both cases [30, 31]. In addition, it was also approved for the H1N1 pandemic vaccine for pregnant woman and young children [32]. Moreover, infants vaccinated with MF59-adjuvant trivalent inactivated influenza vaccine (TIV) presented higher antibody titers and polyfunctional cytokine producing CD4+ T cells than children immunized with the nonadjuvant TIV [33, 34]. The inclusion of MF59 enhanced the low effectiveness of this influenza vaccine in children under 2 years of age. Thereafter, MF59 was tested as an adjuvant for an HBV vaccine, and it was able to induce an immune response one hundred times more potent than the one induced with alum [35].

As with the majority of adjuvants, the mechanisms of action of MF59 are not fully understood. Similar to alum, MF59 effect does not rely on depot formation at the injection site, as its half-life is 42 hours [7, 36]. However, MF59 seems to be a powerful adjuvant due to its ability to induce cellular and humoral responses, including high titers of functional antibodies [37]. Indeed, MF59 is able to stimulate macrophages, resident monocytes, and DCs to secrete several chemokines like CCL4, CCL2, CCL5, and CXCL8 that in turn induce leukocyte recruitment and antigen uptake leading to migration to lymph nodes and triggering the adaptative immune response [32, 38, 39]. Systems biology studies also revealed that MF59 increases expression of the leukocyte transendothelial migration gene cluster and recruitment of MHCII+CD11b+ cells at injection site and this profile may be predictive of robust immune responses [40]. Moreover, an elegant paper by Vono and colleagues showed that transient ATP release is required for innate and adaptive immune responses induced by MF59 [41].

AS03. AS03 is an oil-in-water adjuvant emulsion that contains -tocopherol, squalene, and polysorbate 80 and was developed by GlaxoSmithKline Biologicals [42]. The addition of α-tocopherol to the formulation differentiated AS03 from other oil-in-water emulsion adjuvants [43]. Its first use in humans was together with a malaria vaccine [44]. More recently, this adjuvant has been included for use in human vaccines especially for influenza. Recent clinical trials have showed that oil-in-water adjuvants as AS03 administered with influenza vaccine induced a more robust immune response [45]. Indeed, children aged from 6 to 35 months immunized with one dose of AS03 adjuvant vaccine developed strong immune response that was observed even 6 months after vaccination [46].

AS03 stimulates the immune system by the activation of NF-B, proinflammatory cytokine and chemokine production, recruitment of immune cells, mainly monocytes and macrophages, and induction of high antibody titers. An important issue is to administer AS03 with the antigen at the same injection site at the same time to avoid diminished response [42].

2.1.3. Microparticles

Virus-Like Particles. Virus-like particles (VLPs) are formed by structural viral proteins such as capsid or envelope that mimic intact virus size, shape, and molecule organization with self-assembly properties [47]. Although highly immunogenic because of their self-adjuvant properties, VLPs are noninfective and nonreplicative [48]. The structure of VLPs can be enveloped or nonenveloped depending on the parental virus. Nonenveloped VLPs are only composed by pathogen components with the ability to self-assemble (e.g., HPV) while enveloped VLPs consist of the host cell membrane (an envelope) in combination with the antigen of interest [49]. Other components such as TLRs agonists can also be incorporated into VLPs.

VLPs can induce direct B cell activation, proliferation, and upregulation of genes involved in class switch recombination and somatic hypermutation [50]. In addition, VLPs can bind, activate, and be captured by DCs [51, 52] which in turn lead to T cell immunity. They can also induce cross-presentation to CD8+ T cells [53]. Hence, VLPs are able to induce broad humoral and cellular immune responses including neutralizing antibodies and specific helper CD4+ and cytotoxic CD8+ T cells [54, 55]. There are a few commercially available vaccines that are based on VLPs including Engerix®/Recombivax® (Hepatitis B), Cervarix®/Gardasil® (HPV), and Mosquirix® (malaria) [49]. Currently, several enveloped and nonenveloped VLPs are in clinical development (Table 2).

Adjuvant of clinical trialsTypeStudy phaseApplications

Alum203175 prophylactic1 Pilot, 109 Phase I, 16 Phase I/II, 31 Phase II, 4 Phase II/III, 11 Phase III, 3 Phase IVAllergy, anthrax, botulism, candidiasis, Campylobacter, Clostridium difficile, dengue, encephalitis, Helicobacter pylori, hepatitis b, Herpes simplex, hookworm infection, human papillomavirus, influenza, leishmaniasis, malaria, Meningococcus, Norovirus, Pneumococcus, poliomyelitis, Ross River virus, SARS, schistosomiasis, shigellosis, Staphylococcus, Streptococcus, West Nile virus, yellow fever
28 therapeutic8 Phase I, 5 Phase I/II, 13 Phase II, 2 Phase IIICocaine dependence, colorectal cancer, diabetes, HDL, HIV, hypertension, malaria, melanoma, myasthenia gravis, nicotine dependence, prostate cancer, rhinoconjunctivitis

Freund’s incomplete adjuvant1909 prophylactic4 Phase I, 1 Phase I/II, 2 Phase II, 2 Phase IIIBladder cancer, carcinoma, influenza, malaria, melanoma
181 therapeutic3 Pilot, 63 Phase I, 41 Phase I/II, 64 Phase II, 2 Phase II/III, 8 Phase IIIAcute myeloid leukemia, adenocarcinoma, bladder cancer, bile duct cancer, brain cancer, breast cancer, carcinoma, chronic myeloid leukemia, colorectal cancer, esophageal cancer, gastric cancer, glioblastoma, HIV, HPV-induced cancer, kidney cancer, liver cancer, melanoma, multiple myeloma, multiple sclerosis, non-small-cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer

MF599392 prophylactic 27 Phase I, 6 Phase I/II, 34 Phase II, 3 Phase II/III, 16 Phase III, 6 Phase IVCytomegalovirus infections, influenza, HIV, respiratory syncytial virus
1 therapeutic1 Phase IHIV

Virosomes23 23 prophylactic8 Phase I, 1 Phase I/II, 1 Phase II, 9 Phase III, 4 Phase IVHepatitis A, Hepatitis C, influenza, malaria, vulvovaginal candidiasis

Virus-like particles10195 prophylactic19 Phase I, 6 Phase I/II, 31 Phase II, 36 Phase III, 3 Phase IVChikungunya, Enterovirus 71, HIV, human papillomavirus, influenza, malaria, Norovirus
6 therapeutic2 Phase I, 1 Phase I/II, 3 Phase IIHypertension, melanoma, respiratory syncytial virus

Poly(I:C) 161 prophylactic1 Phase I/IIInfluenza
15 therapeutic2 Pilot, 5 Phase I, 7 Phase I/II, 1 Phase IIAcute myeloid leukemia, allergy, breast cancer, glioblastoma, lymphoma, melanoma, non-small-cell lung cancer, ovarian cancer, prostate cancer

Poly-IC:LC563 prophylactic2 Phase I, 1 Phase IIColorectal cancer, HIV, melanoma
53 therapeutic6 Pilot, 19 Phase I, 17 Phase I/II, 11 Phase IIAcute myeloid leukemia, astrocytoma, bladder cancer, breast cancer, colorectal cancer, epithelial ovarian cancer, glioblastoma, glioma, HIV, low grade B cell lymphoma, melanoma, myeloma, non-small-cell lung cancer, pancreatic adenocarcinoma, prostate cancer

Monophosphoryl lipid A3122 prophylactic7 Phase I, 2 Phase I/II, 6 Phase II, 7 Phase IIIHepatitis B, Herpes simplex, HIV, hookworm infections, malaria, Norovirus, visceral leishmaniasis
9 therapeutic2 Phase I, 1 Phase I/II, 5 Phase II, 1 Phase IIIAllergic rhinitis, cutaneous leishmaniasis, melanoma, type I hypersensitivity

Flagellin66 prophylactic4 Phase I, 1 Phase I/II, 1 Phase IIDiarrhea, influenza, plague

Imiquimod403 prophylactic1 Phase II, 1 Phase II/III, 1 Phase IIIInfluenza, Hepatitis B, Varicella zoster
37 therapeutic2 Pilot, 20 Phase I, 2 Phase I/II, 9 Phase II, 2 Phase III, 2 Phase IVAdenocarcinoma of the prostate, basal cell carcinoma, brain tumor, breast cancer, cervical cancer, ependymoma, gastric cancer, glioblastoma, glioma, human papillomavirus, melanoma, non-small-cell lung cancer, ovarian cancer, prostate cancer, sarcoma

Resiquimod113 prophylactic2 Phase I, 1 Phase I/IIAllergic rhinitis, Hepatitis B, influenza
8 therapeutic2 Pilot, 1 Phase I, 2 Phase I/II, 3 Phase IIAdvanced malignances, bladder cancer, glioma, melanoma

CpG ODN96 prophylactic3 Phase I, 3 Phase I/IIBacterial sepsis, HIV, hookworm infection, malaria
3 therapeutic1 Phase I, 1 Phase I/II, 1 Phase IIAllergic rhinitis, breast cancer, Hepatitis B, HIV

Muramyl dipeptide11 prophylactic1 Phase IHIV

AS0322 22 prophylactic5 Phase I, 3 Phase I/II, 11 Phase II, 1 Phase III, 2 Phase IVDengue, influenza

AS043837 prophylactic2 Phase I, 6 Phase II, 27 Phase III, 2 Phase IVCervical cancer, Herpes simplex, human papillomavirus
1 therapeutic1 Phase II/IIIHepatitis B

Virosomes. Virosomes are a type of VLP platform that is composed of reconstituted viral envelopes with membrane lipids and viral glycoproteins that work as a carrier system for antigens or as adjuvants. Although composed of viral proteins, virosomes are not virulent since the genetic material of the native virus is absent and does not replicate [56]. Virosomes are produced by dissolving the envelope of the virus with a detergent followed by a complete removal of the genetic material of the virus and the nonmembranous proteins. The most used virosomal system is the immunopotentiating reconstituted influenza virosome (IRIV) [57, 58] that contains both the hemagglutinin (HA) and neuraminidase (NA) proteins intercalated within a lipid membrane. Currently, there are five licensed vaccines based on this approach: Inflexal® V, Nasalflu®, and Invivac® for influenza and Epaxal® and Epaxal Junior for Hepatitis A virus [58].

Virosomal HA and sialic acid can interact with APCs and induce particle endocytosis. After the acidification of the endosome, HA changes conformation and the fused antigen can either be released into the cytosol and be processed via MHCI or stay in the endosome and be processed via MHCII pathway. Concomitantly, virosomes increase the expression of costimulatory molecules (CD80, CD86, and CD40) on the APC surface. The whole process leads to CD8+ and CD4+ T cell activation and cytokine production such as IFNγ, TNFα, and GM-CSF [59].

PLA/PLGA. Poly(lactic acid) (PLA) and poly(lactic-coglycolic acid) (PLGA) are biodegradable and biocompatible polymeric micro/nanoparticles that function as a delivery system by encapsulating an antigen or antigen plus adjuvant in the same particle [60, 61]. These particles are produced using techniques such as emulsification/solvent evaporation. Ligands against surface receptors (PRRs, CD1d) have also been loaded in PLGA nanoparticles as an adjuvant to trigger signaling pathways of innate immune responses [62, 63].

The particles are internalized by pinocytosis and clathrin-mediated endocytosis and can rapidly be localized into the cytosol [64]. PLGA can efficiently reach MHCI molecules and cross-present antigens to CD8+ T cells [65]. PLGA nanoparticle delivery system enhances the uptake by APCs [66] allowing prolonged release of the antigen and induces higher immune responses [67] when compared with the soluble counterpart.

PLGA has been used to deliver antigens from different pathogens including Bacillus anthracis [68], Plasmodium vivax [69], and Hepatitis B virus (HBV) [70].

2.2. Immune Potentiators

As stated before, immune potentiators target innate immunity signaling pathways through PRRs like TLRs, RLRs, and NLRs. In general, activation of PRRs by their agonists induces APC activation/maturation and cytokine/chemokine production that ultimately leads to adaptive immune responses. Examples of PRRs agonists include, but are not limited to, poly(I:C), MPL, flagellin, imiquimod, resiquimod, CpG ODN, and MDP (Figure 2).

2.2.1. TLR3 Agonists

Poly(I:C) (polyinosinic:polycytidylic acid) is a synthetic double strand RNA (dsRNA) that mimics viral RNAs and activates TLR3 located within endosomes [71, 72]. Poly(I:C) can also bind to the melanoma differentiation associated gene 5 (MDA5), a cytoplasmic protein that contains two caspase-recruitment domains (CARDs) and a DExD/H-box helicase domain. Results using knockout mice indicate that MDA5 is essential for poly(I:C)-induced IFN production, while TLR3 signaling is critical for IL-12 production. Both seem to regulate IL-6 production [73]. The administration of poly(I:C) activates DCs that quickly produce IL-12 and type I IFN and upregulate MHC II expression [74, 75]. In response to IL-12, NK cells produce IFN that in turn enhances T and B cell immunity. Type I IFN plays a critical role in the induction of Th1 responses and is also associated with cross-presentation [76]. Hence, poly(I:C) impacts APC maturation, antigen processing, and ultimately T and B cell immunity.

Poly(I:C) is the most TLR3 agonist tested as adjuvant against diseases including HIV [77, 78], dengue [79], malaria [80], and cancer [81, 82].

Poly-ICLC (Hiltonol®) is a poly(I:C) synthetic derivative stabilized with poly-L-lysine that is more resistant to RNAses [74, 83]. Several ongoing clinical trials (Table 2) are evaluating poly-ICLC for immunotherapy in patients with cancer [58]. More recently, poly-ICLC was also nasally delivered with a chimeric antibody containing HIV-p24 protein in mice and induced gastrointestinal immune responses [84].

2.2.2. TLR4 Agonists

Monophosphoryl lipid A (MPL) is the detoxified derivative of lipopolysaccharide (LPS) from Gram-negative bacteria (Salmonella minnesota R595). Removal of a phosphate residue from LPS renders MPL just 0.1% of the toxicity from the parental molecule. MPL mediates immune activation by interacting with TLR4 similarly to LPS [72]. MPL preferentially activates the TRIF signaling pathway [85] that triggers different cytokine production when compared to LPS that activates MyD88 and produces high amounts of TNF. Indeed, MPL is able to induce IL-12 and IFN production that promote Th1 responses.

MPL is approved for use in some countries as part of a vaccine against allergy (Pollinex Quattro®) [86] and in Canada for stage IV melanoma (Melacine®) [87]. Ongoing clinical trials evaluate MPL as a potential adjuvant for leishmaniasis, malaria, and Herpes antigens (Table 2).

2.2.3. TLR5 Agonists

Flagellin is the main component of bacterial flagella from both Gram-positive and Gram-negative bacteria and is recognized by the cell surface TLR5. Engagement of TLR5 induces TNF production but flagellin, when administered together with a vaccine antigen of interest, is also able to induce high antibody titers and mixed Th1/Th2 responses [88, 89]. Flagellin can simultaneously target inflammasomes [90] through NLRC4 phosphorylation [91, 92] and NAIP5 [93].

Flagellin can also be fused to the antigen of interest allowing its codelivery to the same APC. Influenza vaccines composed of fused flagellin-hemagglutinin (VAX128 and VAX125) and flagellin-matrix protein (VAX102) completed initial clinical trials [94, 95]. Results demonstrated that immunization with flagellin-fused proteins induced high antibody titers, seroconversion, and protection. Moreover, flagellin was also evaluated as a potent adjuvant to prevent rhinitis in mice [96].

2.2.4. TLR7/8 Agonists

Imiquimod (R837; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) and resiquimod (R848, 4-amino-2-(etoximetil)-a,a-dimethyl-1H-imidazo [4,5-c]quinoline-1-ethanol) are imidazoquinolines with antiviral properties [9799]. Imidazoquinolines mimic single stranded RNAs (ssRNAs) that are recognized by TLR7/8 on endosomes triggering signaling through MyD88 [100102]. Imiquimod is able to activate TLR7, while resiquimod actives TLR7 and TLR8. An important issue is the different TLR7 and TLR8 expression/function between human and mouse cells [103]. In mice, TLR7 is expressed by CD8 DC subsets but not by CD8+ DCs [104]. Nevertheless, in both species TLR7 is expressed on plasmacytoid DCs (pDC), B cells, and neutrophils. In contrast, TLR8 is nonfunctional in mice whereas in humans it is expressed by myeloid DCs (mDC) and monocytes [105]. Activation of both DC subsets in humans (mDCs and pDCs) facilitates type I IFN and IL-12 production [106] and enhances expression of costimulatory molecules, inducing direct and cross-presentation to CD8+ T cells [107], while it also induces NK cell activation [108]. Activation of Th1 cellular immune response can control viral replication, reactivation, and clearance [105]. Furthermore, resiquimod directly stimulates B cell proliferation by mimicking CD40 signal both in humans and in mice that ultimately stimulates antibody and cytokine production [109].

Imiquimod (Aldara) is approved for topical use in humans for treatment of actinic keratosis [110], basal cell carcinoma [111, 112], and genital warts caused by HPV 1, HPV 2, HPV 4, and HPV 7 [113, 114]. Resiquimod was tested in clinical trials to treat lesions caused by human Herpes virus (HSV) [115, 116]. Besides the use in therapy against established infections, these adjuvants are being evaluated for their ability to increase vaccine immunogenicity [78] and also in allergy and tumor therapy such as basocellular carcinoma and central nervous system tumors (Table 2) [117, 118].

Besides imiquimod and resiquimod, other TLR7/8 agonists have also been tested. Among them, we can cite the imidazoquinoline immune response modifier 3M-052 [119], the benzazepine TLR8 agonist, VTX-294 [120], and two benzonaphthyridines compounds SMIP.7-7 and SMIP.7-8 that bind to TLR7 [121].

2.2.5. TLR9 Agonists

CpG ODNs are 18–25 base synthetic oligodeoxynucleotides (ODN) composed of unmethylated CG motifs (cytosine phosphate guanidine) recognized by endosomal TLR9 [122124]. Murine TLR9 is preferentially activated by GACGTT motif while the ideal sequence for human is GTCGTT [125]. TLR9 engagement signals through MyD88, IRAK, and TRAF-6 that ultimately leads to upregulation of costimulatory molecules (CD40, CD80, and CD86) and proinflammatory cytokines (IL-6, IL-12, IL-18, and TNF) [125, 126].

Three different types of CpG ODNs have been identified: A, B, and C [127]. Type A CpG ODNs contain a central phosphodiester palindromic motif in a phosphorothioate backbone and induce type I IFN production by pDCs. B type CpG ODNs have an entire phosphorothioate backbone that protects from degradation by nucleases and stimulates proliferation, IL-6/IgM production by B cells, and IL-6/TNF production by DCs [100, 126]. Type C CpG ODNs combine features of types A and B since they are composed of phosphorothioate backbone with palindromic motif and induce B cell responses as well as type I IFN production by pDCs [128, 129]. In general, CpG ODNs increase antibody responses and polarize to Th1 profile.

One of the most promising clinical results showed that commercial Hepatitis B vaccine administered together with CpG induced higher protective antibody titers after fewer doses both in healthy and in hyporesponsive individuals [130, 131]. Moreover, CpG ODNs have also been used in combination with conventional treatments for cancer [132].

2.2.6. NOD Agonists

Muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine) is a peptidoglycan biologically potent motif found on all bacteria cell walls. MDP was discovered in 1974 as the minimum component of mycobacteria’s cell wall required for the efficacy of complete Freund’s adjuvant [133].

MDP is able to activate NOD2 [134] leading to NF-κB transcription that results in the production of proinflammatory cytokines (TNF, IL-1, IL-6, and IL-8) as well as Th2 cytokines, nitric oxide secretion, enhanced cytotoxicity, and upregulation of adhesion molecules (CD11a, CD11b, CD11c/CD18, CD54) [135]. Studies have focused on the use of MDP for solid tumor therapy based on its ability to stimulate cellular as well as the cytokine response, eliciting antibody production [136].

2.3. Combination of Adjuvants

A recent approach to optimize vaccine immune responses is the use of different adjuvant combinations that could trigger different signaling pathways [137]. Such observation comes from studies using effective live-attenuated vaccines such as yellow fever that induce activation of different PRRs [138].

Based on this observation, one strategy is to use different TLR agonists to trigger activation of different signaling pathways (e.g., MyD88 and TRIF). Previous work tested different TLR agonist combinations in human PBMCs and evaluated cytokine and chemokine production [139]. Combinations of TLR7+TLR9 agonists induced type I IFN whereas TLR4+TLR7/8 synergistically upregulated IFN and IL2; TLR2+TLR7/8 synergistically upregulated IFN and others. MF59 and Carbopol-971P in combination were able to increase specific anti-HIV antibody titers [140]. However, not all combinations increase the magnitude of immune responses. For example, mice immunized with a recombinant HIV gp140 together with MPL plus alum or MDP exert synergic effects on the magnitude and quality of humoral response. However, when the mixture contained MDP plus poly(I:C) or resiquimod, no impact on antibody titers was observed but a significant difference was observed in IgG subclasses [78]. Another study showed that immunization of mice with nanoparticles containing antigens plus TLR4 and TLR7 ligands induced synergistic increases in antigen-specific, neutralizing antibodies when compared to immunization with nanoparticles containing antigens plus a single TLR ligand [141]. DCs activation by different combinations of TLR ligands was also evaluated. Results showed that, in human DCs, agonists of TLR3 and TLR4 potently acted in synergy with a TLR8 agonist and induced higher amounts of IL-12 and IL-23 than those induced by optimal concentrations of single agonists. This synergism led to enhanced and sustained Th1-polarizing capacity [142].

2.3.1. AS01 and AS02

Adjuvant System 01 (AS01) and Adjuvant System 02 (AS02) were the first in this type to be developed and tested in the RTS,S (Plasmodium falciparum circumsporozoite protein) vaccine candidate against malaria [143]. They are composed of MPL and the saponin QS21, but AS01 contains a liposomal suspension while AS02 is an oil-in-water emulsion [144]. When the trial began, AS02 was primarily tested and showed protection against controlled human malaria infection (CHMI) by the bite of infected mosquitoes [143]. However, when AS01 was included a higher production of specific antibody and improved efficacy was observed when compared to AS02 [145, 146]. Several clinical trials are in progress with AS01 and AS02 as vaccine adjuvants against HIV, tuberculosis, and malaria.

2.3.2. AS04

AS04 is composed of a combination of MPL and aluminum salts. Currently, two adjuvant vaccines are licensed: against HPV (Cervarix) [147, 148] and HBV (Fendrix®) [149].

This adjuvant also leads to activation of NF-B, production of proinflammatory cytokines and chemokines, and recruitment of monocytes and macrophages to the injection site, but specifically DCs. It is important to emphasize the need for AS04 and the antigen to be colocalized at the moment of antigen presentation on lymph nodes [144]. The advantage of AS04 for human vaccines is the induction of specific Th1 immune response and production of IL-2 and IFN, a profile weakly induced when alum is used alone [88].

2.4. Mucosal Adjuvants

The first immunization through mucosal surface was accomplished with attenuated poliovirus in 1962. Thereafter, other mucosal vaccines based on Salmonella typhi, Vibrio cholerae [150], rotavirus [151], and influenza virus were developed [152]. Administration by mucosal route has some advantages as needle-free delivery, lower costs, few adverse effects, and induction of local mucosal immunity, an important feature when infection occurs at mucosal routes [150, 153].

The most promising adjuvants for mucosal immunization are bacterial toxins extracted from Escherichia coli (heat-labile enterotoxin, LT) and Vibrio cholerae (cholera toxin, CT), TLRs agonists [flagellin, poly(I:C), CpG ODNs], and novel small molecules (-galactosylceramide, chitosan, etc.). To avoid development of cholera and travellers’ diarrhea symptoms, these toxins have been genetically modified to generate less toxic derivatives (LTK3, LTR-72, and CTB) [154, 155]. Alternative mucosal routes have been evaluated with LT mutants and CT, including nasal, intravaginal, and intrarectal. LTK3 and LTR-72 were shown to induce potent immune responses against influenza virus after oral immunization [156]. Oral immunization with LT was also efficient in protection against H. pylori infection in mice after challenge [157]. Studies that used intranasal delivery of LT as an adjuvant showed that immunization was able to induce strong immune response and protection against Herpes simplex virus [158], S. pneumonia [159], and B. pertussis [160].

Mucosal adjuvants CT and LT amplify B and T responses and stimulate isotype switching to IgA and mixed Th1/Th2 profile [161]. Further studies also demonstrated their ability to increase antigen uptake/presentation and DCs maturation/activation due to antigen permeation across epithelial barriers [162].

Mice intranasally immunized with Plasmodium vivax merozoite surface protein 1 (MSP119) in the presence of the adjuvants CT or LT presented high and long-lasting specific antibody titers. In the same study mice immunized with MSP119 fused to a T cell epitope (PADRE) in the presence of CpG ODN developed lower IgG titers when compared to mice that received CpG ODN plus CT [163]. In a recent study, an anti-HIV chimeric antibody (DEC205-p24) nasally delivered in combination with polyICLC induced polyfunctional immune responses within nasopulmonary lymphoid sites and mucosal gastrointestinal tract [164].

Chitosan is a biopolymer based on glucosamine extracted from a crustacean shell and is a mucosal adjuvant commonly used for intranasal delivery. The adjuvant acts in vitro by the translocation of “tight junctions” that improve transepithelial antigen transport and reduces the mucociliary clearance rate that facilitates antigen phagocytosis [165]. A study using a nontoxic mutant (CRM197) of diphtheria toxin in combination with chitosan showed that intranasal immunization was able to increase Th2 responses and, after a boost with the conventional diphtheria toxoid vaccine, enhanced antigen-specific IFN production [166]. Another study showed that intranasal administration of chitosan and CRM197 was as immunogenic as intramuscular immunization with the conventional diphtheria vaccine adsorbed to alum [167]. Furthermore, H. pylori vaccine with chitosan was used successfully in a therapeutic setting in mice with an equivalent performance as the traditional vaccine adjuvant, cholera toxin (CT). In addition, when infection was not fully eradicated, chitosan immunized mice presented lower bacteria density in the gastric mucosa when compared to CT groups [168].

3. Licensing

The introduction of an adjuvant in a new (or already licensed) vaccine formulation is still a challenge and may take several years. It is of utmost importance to test the compatibility of each component of the vaccine alone and in combination before any trials start [169]. Due to the urgent need to develop vaccines against infectious diseases, the Center for Biologics Evaluation and Research (CBER), a division of the US Food and Drug Administration, launched an important guide to facilitate the development of new formulations [170].

It is recommended that evaluation of safety/immunogenicity of a formulation begins with preclinical tests using an appropriate animal model (Figure 3). At this stage, the evaluation of adjuvant effect on the immune response is also recommended [171]. Of note, control groups composed of adjuvant and the antigen alone should also be included to provide evidence for adjuvant effect. The immunogenicity evaluation may include humoral (e.g., antibody titers, subclasses, avidity, and neutralization) and cellular (e.g., cytokine production, proliferation assays, and cell phenotyping) responses. If an animal model for the disease is available, initial protective efficacy information can be obtained [3].

After preclinical testing and GMP (good manufacturing practice) production of the vaccine formulation, human clinical trials begin. Phase I vaccine studies are conducted in healthy individuals () to evaluate safety—to minimize adverse events and potential risks—and the dosage. Safety concerns include, but are not limited to, pain, granuloma formation, fever, sterile abscess formation, nausea, headache, malaise, and other local or systemic events. Initial immunogenicity information can be obtained from Phase I.

Phase IIa trials are designed to evaluate immunogenicity, tolerability, and safety and typically involve hundreds of volunteers. When tests reach Phases IIb/III, an important goal is to ascertain the immunogenicity and efficacy in the vaccine target population (e.g., children). Another difference is based on the number of volunteers and the study duration; the more the people involved, the longer the trial duration (several years).

After the process that confirms safety and efficacy of the vaccine, it can be licensed and marketed. After that, the formulation undergoes a postmarket safety monitoring, Phase IV, to evaluate additional rare adverse reactions.

4. Concluding Remarks

Adjuvants have been used to increase the immunogenicity of vaccines for almost a century. Until recently, adjuvant selection was empirical, but considerable advances in the field have allowed a rational/targeted use. This information together with an increasing understanding of the immune system will allow the development of effective vaccine formulations. Currently, only few adjuvant vaccines are licensed, but several ones are on clinical development and expected to reach approval in the near future. Finally, we believe that adjuvant selection could highly impact on rational vaccine design.

Competing Interests

The authors declare that they have no competing interests.


This review was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Grants nos. 2014/15061-8 and 2013/11442-4.


  1. J. C. Cox and A. R. Coulter, “Adjuvants—a classification and review of their modes of action,” Vaccine, vol. 15, no. 3, pp. 248–256, 1997. View at: Publisher Site | Google Scholar
  2. G. Ramon, “Sur la toxine et sur I'anatoxine diphtheriques,” Annales de l'Institut Pasteur, vol. 38, pp. 1–10, 1924. View at: Google Scholar
  3. A. D. Pasquale, S. Preiss, F. Silva, and N. Garçon, “Vaccine adjuvants: from 1920 to 2015 and beyond,” Vaccines, vol. 3, no. 2, pp. 320–343, 2015. View at: Publisher Site | Google Scholar
  4. A. T. Glenny, C. G. Pope, H. Waddington, and U. Wallace, “Immunological notes. XVII–XXIV,” The Journal of Pathology and Bacteriology, vol. 29, no. 1, pp. 31–40, 1926. View at: Publisher Site | Google Scholar
  5. E. L. Opie, “An experimental study of protective inoculation with heat killed tubercle bacilli,” The Journal of Experimental Medicine, vol. 66, no. 6, pp. 761–788, 1937. View at: Publisher Site | Google Scholar
  6. B. Guy, “The perfect mix: recent progress in adjuvant research,” Nature Reviews Microbiology, vol. 5, no. 7, pp. 505–517, 2007. View at: Publisher Site | Google Scholar
  7. S. Awate, L. A. Babiuk, and G. Mutwiri, “Mechanisms of action of adjuvants,” Frontiers in Immunology, vol. 4, article 114, 2013. View at: Publisher Site | Google Scholar
  8. S. G. Reed, M. T. Orr, and C. B. Fox, “Key roles of adjuvants in modern vaccines,” Nature Medicine, vol. 19, no. 12, pp. 1597–1608, 2013. View at: Publisher Site | Google Scholar
  9. R. L. Coffman, A. Sher, and R. A. Seder, “Vaccine adjuvants: putting innate immunity to work,” Immunity, vol. 33, no. 4, pp. 492–503, 2010. View at: Publisher Site | Google Scholar
  10. M. Singh and D. T. O'Hagan, “Recent advances in vaccine adjuvants,” Pharmaceutical Research, vol. 19, no. 6, pp. 715–728, 2002. View at: Publisher Site | Google Scholar
  11. A. Pashine, N. M. Valiante, and J. B. Ulmer, “Targeting the innate immune response with improved vaccine adjuvants,” Nature Medicine, vol. 11, no. 4, pp. S63–S68, 2005. View at: Publisher Site | Google Scholar
  12. N. Goto and K. Akama, “Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid,” Microbiology and Immunology, vol. 26, no. 12, pp. 1121–1132, 1982. View at: Publisher Site | Google Scholar
  13. C. Olive, “Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants,” Expert Review of Vaccines, vol. 11, no. 2, pp. 237–256, 2012. View at: Publisher Site | Google Scholar
  14. E. B. Lindblad, “Aluminium compounds for use in vaccines,” Immunology and Cell Biology, vol. 82, no. 5, pp. 497–505, 2004. View at: Publisher Site | Google Scholar
  15. R. K. Gupta, B. E. Rost, E. Relyveld, and G. R. Siber, “Adjuvant properties of aluminum and calcium compounds,” Pharmaceutical Biotechnology, vol. 6, pp. 229–248, 1995. View at: Publisher Site | Google Scholar
  16. V. E. Schijns, “Immunological concepts of vaccine adjuvant activity,” Current Opinion in Immunology, vol. 12, no. 4, pp. 456–463, 2000. View at: Publisher Site | Google Scholar
  17. S. Hutchison, R. A. Benson, V. B. Gibson, A. H. Pollock, P. Garside, and J. M. Brewer, “Antigen depot is not required for alum adjuvanticity,” The FASEB Journal, vol. 26, no. 3, pp. 1272–1279, 2012. View at: Publisher Site | Google Scholar
  18. B. N. Lambrecht, M. Kool, M. A. M. Willart, and H. Hammad, “Mechanism of action of clinically approved adjuvants,” Current Opinion in Immunology, vol. 21, no. 1, pp. 23–29, 2009. View at: Publisher Site | Google Scholar
  19. P. Marrack, A. S. McKee, and M. W. Munks, “Towards an understanding of the adjuvant action of aluminium,” Nature Reviews Immunology, vol. 9, no. 4, pp. 287–293, 2009. View at: Publisher Site | Google Scholar
  20. M. Kool, T. Soullié, M. Van Nimwegen et al., “Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells,” The Journal of Experimental Medicine, vol. 205, no. 4, pp. 869–882, 2008. View at: Publisher Site | Google Scholar
  21. S. C. Eisenbarth, O. R. Colegio, W. O'Connor Jr., F. S. Sutterwala, and R. A. Flavell, “Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants,” Nature, vol. 453, no. 7198, pp. 1122–1126, 2008. View at: Publisher Site | Google Scholar
  22. T. R. Ghimire, R. A. Benson, P. Garside, and J. M. Brewer, “Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro,” Immunology Letters, vol. 147, no. 1-2, pp. 55–62, 2012. View at: Publisher Site | Google Scholar
  23. A. K. Bajaj, S. C. Gupta, R. K. Pandey, K. Misra, S. Rastogi, and A. K. Chatterji, “Aluminium contact sensitivity,” Contact Dermatitis, vol. 37, no. 6, pp. 307–308, 1997. View at: Google Scholar
  24. A. Billiau and P. Matthys, “Modes of action of Freund's adjuvants in experimental models of autoimmune diseases,” Journal of Leukocyte Biology, vol. 70, no. 6, pp. 849–860, 2001. View at: Google Scholar
  25. P. P. Leenaars, C. F. Hendriksen, W. A. de Leeuw et al., “The production of polyclonal antibodies in laboratory animals. the report and recommendations of ECVAM workshop 35,” Alternatives to Laboratory Animals, vol. 27, no. 1, pp. 79–102, 1999. View at: Google Scholar
  26. CCAC, Guidelines on Antibody Production, Canadian Council on Animal Care, 2002.
  27. J. E. Salk and A. M. Laurent, “The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions,” The Journal of Experimental Medicine, vol. 95, no. 5, pp. 429–447, 1952. View at: Publisher Site | Google Scholar
  28. A. Mussener, L. Klareskog, J. C. Lorentzen, and S. Kleinau, “TNF-α dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis,” Scandinavian Journal of Immunology, vol. 42, no. 1, pp. 128–134, 1995. View at: Publisher Site | Google Scholar
  29. L. H. Miller, A. Saul, and S. Mahanty, “Revisiting Freund's incomplete adjuvant for vaccines in the developing world,” Trends in Parasitology, vol. 21, no. 9, pp. 412–414, 2005. View at: Publisher Site | Google Scholar
  30. D. T. O'Hagan, A. Wack, and A. Podda, “MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?” Clinical Pharmacology and Therapeutics, vol. 82, no. 6, pp. 740–744, 2007. View at: Publisher Site | Google Scholar
  31. T. Vesikari, M. Pellegrini, A. Karvonen et al., “Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant,” Pediatric Infectious Disease Journal, vol. 28, no. 7, pp. 563–571, 2009. View at: Publisher Site | Google Scholar
  32. D. T. O'Hagan, G. S. Ott, G. Van Nest, R. Rappuoli, and G. Del Giudice, “The history of MF59® adjuvant: a phoenix that arose from the ashes,” Expert Review of Vaccines, vol. 12, no. 1, pp. 13–30, 2013. View at: Publisher Site | Google Scholar
  33. T. Vesikari, M. Knuf, P. Wutzler et al., “Oil-in-water emulsion adjuvant with influenza vaccine in young children,” The New England Journal of Medicine, vol. 365, no. 15, pp. 1406–1416, 2011. View at: Publisher Site | Google Scholar
  34. H. I. Nakaya, E. Clutterbuck, D. Kazmin et al., “Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood,” Proceedings of the National Academy of Sciences, vol. 113, no. 7, pp. 1853–1858, 2016. View at: Publisher Site | Google Scholar
  35. T. C. Heineman, M. L. Clements-Mann, G. A. Poland et al., “A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant,” Vaccine, vol. 17, no. 22, pp. 2769–2778, 1999. View at: Publisher Site | Google Scholar
  36. M. Dupuis, D. M. McDonald, and G. Ott, “Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice,” Vaccine, vol. 18, no. 5-6, pp. 434–439, 1999. View at: Publisher Site | Google Scholar
  37. I. Stephenson, R. Bugarini, K. G. Nicholson et al., “Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy,” Journal of Infectious Diseases, vol. 191, no. 8, pp. 1210–1215, 2005. View at: Publisher Site | Google Scholar
  38. A. Seubert, E. Monaci, M. Pizza, D. T. O'hagan, and A. Wack, “The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells,” The Journal of Immunology, vol. 180, no. 8, pp. 5402–5412, 2008. View at: Publisher Site | Google Scholar
  39. E. De Gregorio, E. Caproni, and J. B. Ulmer, “Vaccine adjuvants: mode of action,” Frontiers in Immunology, vol. 4, article 214, 2013. View at: Publisher Site | Google Scholar
  40. F. Mosca, E. Tritto, A. Muzzi et al., “Molecular and cellular signatures of human vaccine adjuvants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10501–10506, 2008. View at: Publisher Site | Google Scholar
  41. M. Vono, M. Taccone, P. Caccin et al., “The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 52, pp. 21095–21100, 2013. View at: Publisher Site | Google Scholar
  42. N. Garçon, D. W. Vaughn, and A. M. Didierlaurent, “Development and evaluation of AS03, an adjuvant system containing α-tocopherol and squalene in an oil-in-water emulsion,” Expert Review of Vaccines, vol. 11, no. 3, pp. 349–366, 2012. View at: Publisher Site | Google Scholar
  43. S. Morel, A. Didierlaurent, P. Bourguignon et al., “Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity,” Vaccine, vol. 29, no. 13, pp. 2461–2473, 2011. View at: Publisher Site | Google Scholar
  44. J. A. Stoute, M. Slaoui, D. G. Heppner et al., “A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria,” The New England Journal of Medicine, vol. 336, no. 2, pp. 86–91, 1997. View at: Publisher Site | Google Scholar
  45. J. Díez-Domingo, M. Garcés-Sanchez, J.-M. Baldó et al., “Immunogenicity and safety of H5N1 A/vietnam/1194/2004 (clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study,” Pediatric Infectious Disease Journal, vol. 29, no. 6, pp. e35–e46, 2010. View at: Publisher Site | Google Scholar
  46. A. C. Martinez, I. S. De La Cueva, P. Boutet, C. V. Abeele, I. Smolenov, and J.-M. Devaster, “A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months,” Human Vaccines and Immunotherapeutics, vol. 10, no. 7, pp. 1959–1968, 2014. View at: Publisher Site | Google Scholar
  47. C. Muratori, R. Bona, and M. Federico, “Lentivirus-based virus-like particles as a new protein delivery tool,” Methods in Molecular Biology, vol. 614, pp. 111–124, 2010. View at: Publisher Site | Google Scholar
  48. C. Huret, D. Desjardins, M. Miyalou et al., “Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice,” Vaccine, vol. 31, no. 11, pp. 1540–1547, 2013. View at: Publisher Site | Google Scholar
  49. N. Kushnir, S. J. Streatfield, and V. Yusibov, “Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development,” Vaccine, vol. 31, no. 1, pp. 58–83, 2012. View at: Publisher Site | Google Scholar
  50. L. Zhang, D. Pasquale, M. Le, R. Patel, and S. Mehdi, “Isolated splenic metastasis in a patient with two distinct genitourinary malignancies,” Journal of Community and Supportive Oncology, vol. 13, no. 6, pp. 229–230, 2015. View at: Google Scholar
  51. C. M. Bosio, B. D. Moore, K. L. Warfield et al., “Ebola and Marburg virus-like particles activate human myeloid dendritic cells,” Virology, vol. 326, no. 2, pp. 280–287, 2004. View at: Publisher Site | Google Scholar
  52. D. M. Da Silva, S. C. Fausch, J. S. Verbeek, and W. M. Kast, “Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcγ receptors and contributes to acquisition of T cell immunity,” The Journal of Immunology, vol. 178, no. 12, pp. 7587–7597, 2007. View at: Publisher Site | Google Scholar
  53. C. Dalba, B. Bellier, N. Kasahara, and D. Klatzmann, “Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines,” Molecular Therapy, vol. 15, no. 3, pp. 457–466, 2007. View at: Publisher Site | Google Scholar
  54. D. M. Smith, J. K. Simon, and J. R. Baker Jr., “Applications of nanotechnology for immunology,” Nature Reviews Immunology, vol. 13, no. 8, pp. 592–605, 2013. View at: Publisher Site | Google Scholar
  55. L. Buonaguro, L. Racioppi, M. L. Tornesello et al., “Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A,” Antiviral Research, vol. 54, no. 3, pp. 189–201, 2002. View at: Publisher Site | Google Scholar
  56. R. Zurbriggen, “Immunostimulating reconstituted influenza virosomes,” Vaccine, vol. 21, no. 9-10, pp. 921–924, 2003. View at: Publisher Site | Google Scholar
  57. M. J. Copland, T. Rades, N. M. Davies, and M. A. Baird, “Lipid based particulate formulations for the delivery of antigen,” Immunology and Cell Biology, vol. 83, no. 2, pp. 97–105, 2005. View at: Publisher Site | Google Scholar
  58. M. A. Morse, R. Chapman, J. Powderly et al., “Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients,” Clinical Cancer Research, vol. 17, no. 14, pp. 4844–4853, 2011. View at: Publisher Site | Google Scholar
  59. D. Felnerova, J.-F. Viret, R. Glück, and C. Moser, “Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs,” Current Opinion in Biotechnology, vol. 15, no. 6, pp. 518–529, 2004. View at: Publisher Site | Google Scholar
  60. P. Elamanchili, C. M. E. Lutsiak, S. Hamdy, M. Diwan, and J. Samuel, “‘Pathogen-mimicking’ nanoparticles for vaccine delivery to dendritic cells,” Journal of Immunotherapy, vol. 30, no. 4, pp. 378–395, 2007. View at: Publisher Site | Google Scholar
  61. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Préat, “PLGA-based nanoparticles: an overview of biomedical applications,” Journal of Controlled Release, vol. 161, no. 2, pp. 505–522, 2012. View at: Publisher Site | Google Scholar
  62. L. J. Cruz, P. J. Tacken, R. Fokkink et al., “Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro,” Journal of Controlled Release, vol. 144, no. 2, pp. 118–126, 2010. View at: Publisher Site | Google Scholar
  63. E. MacHo Fernandez, J. Chang, J. Fontaine et al., “Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles,” International Journal of Pharmaceutics, vol. 423, no. 1, pp. 45–54, 2012. View at: Publisher Site | Google Scholar
  64. J. K. Vasir and V. Labhasetwar, “Biodegradable nanoparticles for cytosolic delivery of therapeutics,” Advanced Drug Delivery Reviews, vol. 59, no. 8, pp. 718–728, 2007. View at: Publisher Site | Google Scholar
  65. H. Shen, A. L. Ackerman, V. Cody et al., “Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles,” Immunology, vol. 117, no. 1, pp. 78–88, 2006. View at: Publisher Site | Google Scholar
  66. T. T. Beaudette, E. M. Bachelder, J. A. Cohen et al., “In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines,” Molecular Pharmaceutics, vol. 6, no. 4, pp. 1160–1169, 2009. View at: Publisher Site | Google Scholar
  67. S. de Jong, G. Chikh, L. Sekirov et al., “Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN,” Cancer Immunology, Immunotherapy, vol. 56, no. 8, pp. 1251–1264, 2007. View at: Publisher Site | Google Scholar
  68. M. Manish, A. Rahi, M. Kaur, R. Bhatnagar, and S. Singh, “A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge,” PLoS ONE, vol. 8, no. 4, Article ID e61885, 2013. View at: Publisher Site | Google Scholar
  69. J. J. Moon, H. Suh, M. E. Polhemus, C. F. Ockenhouse, A. Yadava, and D. J. Irvine, “Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine,” PLoS ONE, vol. 7, no. 2, Article ID e31472, 2012. View at: Publisher Site | Google Scholar
  70. C. Thomas, A. Rawat, L. Hope-Weeks, and F. Ahsan, “Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine,” Molecular Pharmaceutics, vol. 8, no. 2, pp. 405–415, 2011. View at: Publisher Site | Google Scholar
  71. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001. View at: Publisher Site | Google Scholar
  72. M. S. Duthie, H. P. Windish, C. B. Fox, and S. G. Reed, “Use of defined TLR ligands as adjuvants within human vaccines,” Immunological Reviews, vol. 239, no. 1, pp. 178–196, 2011. View at: Publisher Site | Google Scholar
  73. H. Kato, O. Takeuchi, S. Sato et al., “Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses,” Nature, vol. 441, no. 1, pp. 101–105, 2006. View at: Publisher Site | Google Scholar
  74. M. P. Longhi, C. Trumpfheller, J. Idoyaga et al., “Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant,” The Journal of Experimental Medicine, vol. 206, no. 7, pp. 1589–1602, 2009. View at: Publisher Site | Google Scholar
  75. G. M. Davey, M. Wojtasiak, A. I. Proietto, F. R. Carbone, W. R. Heath, and S. Bedoui, “Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo,” Journal of Immunology, vol. 184, no. 5, pp. 2243–2246, 2010. View at: Publisher Site | Google Scholar
  76. O. Schulz, S. S. Diebold, M. Chen et al., “Toll-like receptor 3 promotes cross-priming to virus-infected cells,” Nature, vol. 433, no. 7028, pp. 887–892, 2005. View at: Publisher Site | Google Scholar
  77. C. Trumpfheller, M. Caskey, G. Nchinda et al., “The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2574–2579, 2008. View at: Publisher Site | Google Scholar
  78. J. S. Apostólico, S. B. Boscardin, M. M. Yamamoto et al., “HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost,” PLOS ONE, vol. 11, no. 1, Article ID e0145637, 2016. View at: Publisher Site | Google Scholar
  79. H. R. Henriques, E. V. Rampazo, A. J. S. Gonçalves et al., “Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge,” PLoS Neglected Tropical Diseases, vol. 7, no. 7, article e2330, 2013. View at: Google Scholar
  80. K. Tewari, B. J. Flynn, S. B. Boscardin et al., “Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates,” Vaccine, vol. 28, no. 45, pp. 7256–7266, 2010. View at: Publisher Site | Google Scholar
  81. G. Forte, A. Rega, S. Morello et al., “Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer,” The Journal of Immunology, vol. 188, no. 11, pp. 5357–5364, 2012. View at: Publisher Site | Google Scholar
  82. T. Nagato, Y.-R. Lee, Y. Harabuchi, and E. Celis, “Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 t-cell responses against established tumors,” Clinical Cancer Research, vol. 20, no. 5, pp. 1223–1234, 2014. View at: Publisher Site | Google Scholar
  83. C. Stahl-Hennig, M. Eisenblätter, E. Jasny et al., “Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques,” PLoS Pathogens, vol. 5, no. 4, Article ID e1000373, 2009. View at: Publisher Site | Google Scholar
  84. D. Ruane, Y. Do, L. Brane et al., “A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract,” Mucosal Immunology, 2016. View at: Publisher Site | Google Scholar
  85. V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell, “The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4,” Science, vol. 316, no. 5831, pp. 1628–1632, 2007. View at: Publisher Site | Google Scholar
  86. M. Hopkins, B. G. Lees, D. G. Richardson, S. R. Woroniecki, and A. W. Wheeler, “Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL),” Allergologia et Immunopathologia, vol. 29, no. 6, pp. 245–254, 2001. View at: Publisher Site | Google Scholar
  87. M. S. Mitchell, “Perspective on allogeneic melanoma lysates in active specific immunotherapy,” Seminars in Oncology, vol. 25, no. 6, pp. 623–635, 1998. View at: Google Scholar
  88. A. M. Didierlaurent, S. Morel, L. Lockman et al., “AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity,” The Journal of Immunology, vol. 183, no. 10, pp. 6186–6197, 2009. View at: Publisher Site | Google Scholar
  89. J. W. Huleatt, A. R. Jacobs, J. Tang et al., “Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity,” Vaccine, vol. 25, no. 4, pp. 763–775, 2007. View at: Publisher Site | Google Scholar
  90. J. Garaude, A. Kent, N. van Rooijen, and J. M. Blander, “Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses,” Science Translational Medicine, vol. 4, no. 120, Article ID 120ra16, 2012. View at: Publisher Site | Google Scholar
  91. Y. Zhao, J. Yang, J. Shi et al., “The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus,” Nature, vol. 477, no. 7366, pp. 596–600, 2011. View at: Publisher Site | Google Scholar
  92. M. Matusiak, N. Van Opdenbosch, L. Vande Walle, J.-C. Sirard, D.-T. Kanneganti, and M. Lamkanfi, “Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 5, pp. 1541–1546, 2015. View at: Publisher Site | Google Scholar
  93. E. M. Kofoed and R. E. Vance, “Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity,” Nature, vol. 477, no. 7366, pp. 592–597, 2011. View at: Publisher Site | Google Scholar
  94. C. B. Turley, R. E. Rupp, C. Johnson et al., “Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults,” Vaccine, vol. 29, no. 32, pp. 5145–5152, 2011. View at: Publisher Site | Google Scholar
  95. D. N. Taylor, J. J. Treanor, E. A. Sheldon et al., “Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response,” Vaccine, vol. 30, no. 39, pp. 5761–5769, 2012. View at: Publisher Site | Google Scholar
  96. E. H. Kim, J. H. Kim, R. Samivel et al., “Intralymphatic treatment of flagellin-ovalbumin mixture reduced allergic inflammation in murine model of allergic rhinitis,” Allergy, 2016. View at: Publisher Site | Google Scholar
  97. R. D. Weeratna, S. R. Makinen, M. J. McCluskie, and H. L. Davis, “TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848),” Vaccine, vol. 23, no. 45, pp. 5263–5270, 2005. View at: Publisher Site | Google Scholar
  98. D. I. Bernstein, C. J. Harrison, M. A. Tomai, and R. L. Miller, “Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment,” Journal of Infectious Diseases, vol. 183, no. 6, pp. 844–849, 2001. View at: Publisher Site | Google Scholar
  99. C. J. Harrison, R. L. Miller, and D. I. Bernstein, “Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 9, pp. 2059–2064, 1994. View at: Publisher Site | Google Scholar
  100. H. Hemmi, T. Kaisho, K. Takeda, and S. Akira, “The roles of toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets,” The Journal of Immunology, vol. 170, no. 6, pp. 3059–3064, 2003. View at: Publisher Site | Google Scholar
  101. S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004. View at: Publisher Site | Google Scholar
  102. N. M. Shukla, S. S. Malladi, C. A. Mutz, R. Balakrishna, and S. A. David, “Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues,” Journal of Medicinal Chemistry, vol. 53, no. 11, pp. 4450–4465, 2010. View at: Publisher Site | Google Scholar
  103. S. Gnjatic, N. B. Sawhney, and N. Bhardwaj, “Toll-like receptor agonists are they good adjuvants?” Cancer Journal, vol. 16, no. 4, pp. 382–391, 2010. View at: Publisher Site | Google Scholar
  104. A. Iwasaki and R. Medzhitov, “Toll-like receptor control of the adaptive immune responses,” Nature Immunology, vol. 5, no. 10, pp. 987–995, 2004. View at: Publisher Site | Google Scholar
  105. M. Jurk, F. Heil, J. Vollmer et al., “Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848,” Nature Immunology, vol. 3, no. 6, article 499, 2002. View at: Publisher Site | Google Scholar
  106. K. Loré, M. R. Betts, J. M. Brenchley et al., “Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses,” The Journal of Immunology, vol. 171, no. 8, pp. 4320–4328, 2003. View at: Publisher Site | Google Scholar
  107. A. Le Bon, N. Etchart, C. Rossmann et al., “Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon,” Nature Immunology, vol. 4, no. 10, pp. 1009–1015, 2003. View at: Publisher Site | Google Scholar
  108. C. Liu, Y. Lou, G. Lizée et al., “Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice,” The Journal of Clinical Investigation, vol. 118, no. 3, pp. 1165–1175, 2008. View at: Publisher Site | Google Scholar
  109. G. A. Bishop, L. M. Ramirez, M. Baccam, L. K. Busch, L. K. Pederson, and M. A. Tomai, “The immune response modifier resiquimod mimics CD40-induced B cell activation,” Cellular Immunology, vol. 208, no. 1, pp. 9–17, 2001. View at: Publisher Site | Google Scholar
  110. C. V. Caperton and B. Berman, “Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses,” Clinical, Cosmetic and Investigational Dermatology, vol. 4, pp. 35–40, 2011. View at: Publisher Site | Google Scholar
  111. V. Oldfield, G. M. Keating, and C. M. Perry, “Imiquimod: in superficial basal cell carcinoma,” American Journal of Clinical Dermatology, vol. 6, no. 3, pp. 195–202, 2005. View at: Publisher Site | Google Scholar
  112. G. Micali, F. Lacarrubba, M. R. Nasca, S. Ferraro, and R. A. Schwartz, “Topical pharmacotherapy for skin cancer: part II. Clinical applications,” Journal of the American Academy of Dermatology, vol. 70, no. 6, pp. 979.e1–979.e12, 2014. View at: Publisher Site | Google Scholar
  113. U. R. Hengge, S. Esser, T. Schultewolter et al., “Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum,” British Journal of Dermatology, vol. 143, no. 5, pp. 1026–1031, 2000. View at: Publisher Site | Google Scholar
  114. T. Rosen, A. Nelson, and K. Ault, “Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men,” Cutis, vol. 96, no. 4, pp. 277–282, 2015. View at: Google Scholar
  115. K. E. Mark, L. Corey, T.-C. Meng et al., “Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial,” Journal of Infectious Diseases, vol. 195, no. 9, pp. 1324–1331, 2007. View at: Publisher Site | Google Scholar
  116. K. H. Fife, T.-C. Meng, D. G. Ferris, and P. Liu, “Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 477–482, 2008. View at: Publisher Site | Google Scholar
  117. D. H. Dockrell and G. R. Kinghorn, “Imiquimod and resiquimod as novel immunomodulators,” Journal of Antimicrobial Chemotherapy, vol. 48, no. 6, pp. 751–755, 2001. View at: Publisher Site | Google Scholar
  118. R. M. Prins, N. Craft, K. W. Bruhn et al., “The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity,” The Journal of Immunology, vol. 176, no. 1, pp. 157–164, 2006. View at: Publisher Site | Google Scholar
  119. D. Smirnov, J. J. Schmidt, J. T. Capecchi, and P. D. Wightman, “Vaccine adjuvant activity of 3m-052: an imidazoquinoline designed for local activity without systemic cytokine induction,” Vaccine, vol. 29, no. 33, pp. 5434–5442, 2011. View at: Publisher Site | Google Scholar
  120. D. J. Dowling, Z. Tan, Z. M. Prokopowicz et al., “The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes,” PLoS ONE, vol. 8, no. 3, Article ID e58164, 2013. View at: Publisher Site | Google Scholar
  121. C. C. N. Wu, B. Crain, S. Yao et al., “Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand,” Journal of Innate Immunity, vol. 6, no. 3, pp. 315–324, 2014. View at: Publisher Site | Google Scholar
  122. P. Dasari, I. C. Nicholson, G. Hodge, G. W. Dandie, and H. Zola, “Expression of toll-like receptors on B lymphocytes,” Cellular Immunology, vol. 236, no. 1-2, pp. 140–145, 2005. View at: Publisher Site | Google Scholar
  123. L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle, “Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer,” Pharmacological Reviews, vol. 61, no. 2, pp. 177–197, 2009. View at: Publisher Site | Google Scholar
  124. D. M. Foureau, D. W. Mielcarz, L. C. Menard et al., “TLR9-dependent induction of intestinal α-defensins by Toxoplasma gondii,” The Journal of Immunology, vol. 184, no. 12, pp. 7022–7029, 2010. View at: Publisher Site | Google Scholar
  125. A. M. Krieg, “CpG DNA: trigger of sepsis, mediator of protection, or both?” Scandinavian Journal of Infectious Diseases, vol. 35, no. 9, pp. 653–659, 2003. View at: Publisher Site | Google Scholar
  126. D. M. Klinman, “Use of CpG oligodeoxynucleotides as immunoprotective agents,” Expert Opinion on Biological Therapy, vol. 4, no. 6, pp. 937–946, 2004. View at: Publisher Site | Google Scholar
  127. J. Vollmer, R. Weeratna, P. Payette et al., “Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities,” European Journal of Immunology, vol. 34, no. 1, pp. 251–262, 2004. View at: Publisher Site | Google Scholar
  128. G. Hartmann, J. Battiany, H. Poeck et al., “Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells,” European Journal of Immunology, vol. 33, no. 6, pp. 1633–1641, 2003. View at: Publisher Site | Google Scholar
  129. J. D. Marshall, E. M. Hessel, J. Gregorio et al., “Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells,” Nucleic Acids Research, vol. 31, no. 17, pp. 5122–5133, 2003. View at: Publisher Site | Google Scholar
  130. S. A. Halperin, S. Dobson, S. McNeil et al., “Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults,” Vaccine, vol. 24, no. 1, pp. 20–26, 2006. View at: Publisher Site | Google Scholar
  131. M. Barry and C. Cooper, “Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy,” Expert Opinion on Biological Therapy, vol. 7, no. 11, pp. 1731–1737, 2007. View at: Publisher Site | Google Scholar
  132. C. Schmidt, “Clinical setbacks for toll-like receptor 9 agonists in cancer,” Nature Biotechnology, vol. 25, no. 8, pp. 825–826, 2007. View at: Publisher Site | Google Scholar
  133. F. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer, “Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives,” Biochemical and Biophysical Research Communications, vol. 59, no. 4, pp. 1317–1325, 1974. View at: Publisher Site | Google Scholar
  134. S. E. Girardin, I. G. Boneca, J. Viala et al., “Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 8869–8872, 2003. View at: Publisher Site | Google Scholar
  135. K. Dzierzbicka, A. Wardowska, and P. Trzonkowski, “Recent developments in the synthesis and biological activity of muramylpeptides,” Current Medicinal Chemistry, vol. 18, no. 16, pp. 2438–2451, 2011. View at: Publisher Site | Google Scholar
  136. P. T. P. Kaumaya, K. C. Foy, J. Garrett et al., “Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5270–5277, 2009. View at: Publisher Site | Google Scholar
  137. S. Lee and M. T. Nguyen, “Recent advances of vaccine adjuvants for infectious diseases,” Immune Network, vol. 15, no. 2, pp. 51–57, 2015. View at: Publisher Site | Google Scholar
  138. T. Querec, S. Bennouna, S. Alkan et al., “Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 413–424, 2006. View at: Publisher Site | Google Scholar
  139. T. K. Ghosh, D. J. Mickelson, J. Fink et al., “Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses,” Cellular Immunology, vol. 243, no. 1, pp. 48–57, 2006. View at: Publisher Site | Google Scholar
  140. R. P. J. Lai, M. S. Seaman, P. Tonks et al., “Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants,” PLoS ONE, vol. 7, no. 4, Article ID e35083, 2012. View at: Publisher Site | Google Scholar
  141. S. P. Kasturi, I. Skountzou, R. A. Albrecht et al., “Programming the magnitude and persistence of antibody responses with innate immunity,” Nature, vol. 470, no. 7335, pp. 543–550, 2011. View at: Publisher Site | Google Scholar
  142. G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia, “Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells,” Nature Immunology, vol. 6, no. 8, pp. 769–776, 2005. View at: Publisher Site | Google Scholar
  143. S. L. Hoffman, J. Vekemans, T. L. Richie, and P. E. Duffy, “The March toward malaria vaccines,” American Journal of Preventive Medicine, vol. 49, no. 6, supplement 4, pp. S319–S333, 2015. View at: Publisher Site | Google Scholar
  144. N. Garçon, P. Chomez, and M. Van Mechelen, “GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives,” Expert Review of Vaccines, vol. 6, no. 5, pp. 723–739, 2007. View at: Publisher Site | Google Scholar
  145. K. E. Kester, J. F. Cummings, O. Ofori-Anyinam et al., “Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection,” Journal of Infectious Diseases, vol. 200, no. 3, pp. 337–346, 2009. View at: Publisher Site | Google Scholar
  146. G. Leroux-Roels, I. Leroux-Roels, F. Clement et al., “Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults,” Human Vaccines and Immunotherapeutics, vol. 10, no. 8, pp. 2211–2219, 2014. View at: Publisher Site | Google Scholar
  147. D. M. Harper, E. L. Franco, C. Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at: Publisher Site | Google Scholar
  148. J. Paavonen, D. Jenkins, F. X. Bosch et al., “Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial,” The Lancet, vol. 369, no. 9580, pp. 2161–2170, 2007. View at: Publisher Site | Google Scholar
  149. S. Thoelen, N. De Clercq, and N. Tornieporth, “A prophylactic hepatitis B vaccine with a novel adjuvant system,” Vaccine, vol. 19, no. 17–19, pp. 2400–2403, 2001. View at: Publisher Site | Google Scholar
  150. M. M. Levine, “Immunization against bacterial diseases of the intestine,” Journal of Pediatric Gastroenterology and Nutrition, vol. 31, no. 4, pp. 336–355, 2000. View at: Publisher Site | Google Scholar
  151. A. Z. Kapikian, Y. Hoshino, R. M. Chanock, and I. Perez-Schael, “Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children,” Journal of Infectious Diseases, vol. 174, supplement 1, pp. S65–S72, 1996. View at: Publisher Site | Google Scholar
  152. R. B. Belshe, P. M. Mendelman, J. Treanor et al., “The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children,” The New England Journal of Medicine, vol. 338, no. 20, pp. 1405–1412, 1998. View at: Publisher Site | Google Scholar
  153. H. Savelkoul, V. Ferro, M. Strioga, and V. Schijns, “Choice and design of adjuvants for parenteral and mucosal vaccines,” Vaccines, vol. 3, no. 1, pp. 148–171, 2015. View at: Publisher Site | Google Scholar
  154. B. L. Dickinson and J. D. Clements, “Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity,” Infection and Immunity, vol. 63, no. 5, pp. 1617–1623, 1995. View at: Google Scholar
  155. G. Douce, C. Turcotte, I. Cropley et al., “Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1644–1648, 1995. View at: Publisher Site | Google Scholar
  156. J. D. Barackman, G. Ott, S. Pine, and D. T. O'Hagan, “Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization,” Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 3, pp. 652–657, 2001. View at: Publisher Site | Google Scholar
  157. M. Marchetti, M. Rossi, V. Giannelli et al., “Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant,” Vaccine, vol. 16, no. 1, pp. 33–37, 1998. View at: Publisher Site | Google Scholar
  158. D. O'Hagan, C. Goldbeck, M. Ugozzoli, G. Ott, and R. L. Burke, “Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs,” Vaccine, vol. 17, no. 18, pp. 2229–2236, 1999. View at: Publisher Site | Google Scholar
  159. H. Jakobsen, D. Schulz, M. Pizza, R. Rappuoli, and I. Jónsdóttir, “Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections,” Infection and Immunity, vol. 67, no. 11, pp. 5892–5897, 1999. View at: Google Scholar
  160. E. J. Ryan, E. Mcneela, G. A. Murphy et al., “Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells,” Infection and Immunity, vol. 67, no. 12, pp. 6270–6280, 1999. View at: Google Scholar
  161. J. H. Rhee, S. E. Lee, and S. Y. Kim, “Mucosal vaccine adjuvants update,” Clinical and Experimental Vaccine Research, vol. 1, no. 1, pp. 50–63, 2012. View at: Publisher Site | Google Scholar
  162. M. C. Gagliardi, F. Sallusto, M. Marinaro et al., “Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming,” European Journal of Immunology, vol. 30, no. 8, pp. 2394–2403, 2000. View at: Publisher Site | Google Scholar
  163. D. Y. Bargieri, D. S. Rosa, M. A. S. Lasaro, L. C. S. Ferreira, I. S. Soares, and M. M. Rodrigues, “Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route,” Memorias do Instituto Oswaldo Cruz, vol. 102, no. 3, pp. 313–317, 2007. View at: Publisher Site | Google Scholar
  164. D. Ruane, A. Chorny, H. Lee et al., “Microbiota regulate the ability of lung dendritic cells to induce IgA class-switch recombination and generate protective gastrointestinal immune responses,” The Journal of Experimental Medicine, vol. 213, no. 1, pp. 53–73, 2016. View at: Publisher Site | Google Scholar
  165. S. A. Moschos, V. W. Bramwell, S. Somavarapu, and H. O. Alpar, “Adjuvant synergy: the effects of nasal coadministration of adjuvants,” Immunology and Cell Biology, vol. 82, no. 6, pp. 628–637, 2004. View at: Publisher Site | Google Scholar
  166. E. A. McNeela, I. Jabbal-Gill, L. Illum et al., “Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan,” Vaccine, vol. 22, no. 8, pp. 909–914, 2004. View at: Publisher Site | Google Scholar
  167. K. H. G. Mills, C. Cosgrove, E. A. McNeela et al., “Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A,” Infection and Immunity, vol. 71, no. 2, pp. 726–732, 2003. View at: Publisher Site | Google Scholar
  168. Y. Gong, L. Tao, F. Wang et al., “Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine,” Molecular Medicine Reports, vol. 12, no. 3, pp. 4123–4132, 2015. View at: Publisher Site | Google Scholar
  169. F. Verdier, “Non-clinical vaccine safety assessment,” Toxicology, vol. 174, no. 1, pp. 37–43, 2002. View at: Publisher Site | Google Scholar
  170. M. J. Brennan, “The US food and drug administration provides a pathway for licensing vaccines for global diseases,” PLoS Medicine, vol. 6, no. 7, Article ID e1000095, 2009. View at: Publisher Site | Google Scholar
  171. T. E. M. Agency, Guideline on Adjuvants in Vaccines, T. E. M. Agency, London, UK, 2005.

Copyright © 2016 Juliana de Souza Apostólico et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

7202 Views | 2556 Downloads | 51 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder